If history is any guide, there may be trouble ahead for shares of Ventas (NYSE:VTR). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
Land & Buildings Comments on Ventas ISS Report
ISS Supports Many of Land & Buildings' Arguments, Including that Ventas Has Underperformed Welltower From a TSR Perspective "In All Analyzed Time
If history is any guide, there may be good fortune ahead for shares of Ventas (NYSE:VTR). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.
Ventas (NYSE:VTR) has outperformed the market over the past 20 years by 1.04% on an annualized basis producing an average annual return of 8.02%. Currently, Ventas has a market capitalization of $23.65 billion.